A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- NCT01409213
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the Deutsche Diabetes Gesellschaft (DDG) on October 13, 2008
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1523
Inclusion Criteria
- Newly diagnosed with Type 2 diabetes in whom treatment with metformin in
the individual maximal tolerated dose (at least four weeks on stable dose) resulted in
HbA1c >6.5%
- No contraindication or intolerability to metformin
Exclusion Criteria
- Currently being administered a combination therapy for the treatment of their Type 2 diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change From Baseline for Mean Fasting Blood Glucose (FBG) Baseline and end of Observation (up to Month 6) Change from baseline was defined as mean FBG baseline value minus mean FBG end of observation value.
Change From Baseline for Mean Hemoglobin A1c (HbA1C) Baseline and end of Observation (up to Month 6) Change from baseline was defined as mean HbA1c baseline value minus the mean HbA1c end of observation value.
- Secondary Outcome Measures
Name Time Method